Image source: Getty Images.
Continue Reading Below
Shares ofRaptor Pharmaceuticals (NASDAQ: RPTP), a rare-disease drugmaker, gained as much as 20% in pre-market trading today. This hefty surge is the result of a reported $800 million all-cash buyout offer from Horizon Pharma (NASDAQ: HZNP). According to the press release, this deal should close sometime in the fourth quarter of 2016.
This deal further strengthens Horizon's growing orphan disease franchise, and supports the drugmaker's pivot away from the controversial specialty pharma space. By acquiring Raptor, Horizon will add to its portfolio of orphan drugsthe nephropathic cystinosis (a rare metabolic disorder)treatmentProcysbi and the cystic fibrosis medication Quinsair.
Although this acquisition will reportedly add $675 million in debt to Horizon's already highly levered balance sheet, it is expected to beaccretive to the company's adjusted EBITDA in 2017. But perhaps most importantly, this deal shows that Horizon is indeed serious about transforming into an orphan drug company in order to put the headwinds surrounding the specialty pharma drug pricing controversy behind it. That's really good news for shareholders in this politically charged environment.
After all, drugmakers could face some serious pushback from lawmakers and pharmacy benefit managers over drug pricing points once the U.S. presidential election wraps up. And Horizon would almost certainly be a prime target due to products like thearthritis drug Duexis, which has drawn tremendous heat over in the past as a result of its sky-high price tag.
All told, this deal seems like a particularly good fit for Horizon, especially since it should set the company up for sustainable, long-term growth going forward. That's why it might be worth grabbing some shares of this mid-cap growth stock today.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.